- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04895475
Antibody Detection of Vaccine-Induced Secretory Effects (ADVISE)
August 28, 2023 updated by: Children's Hospital Medical Center, Cincinnati
The purpose of this research study is to conduct a prospective longitudinal surveillance research study, enrolling approximately 60 lactating mothers who receive the SARS-CoV-2 vaccine, and then following their clinical and laboratory parameters for up to 12 months.
The overall goal is to investigate the characteristics of antibody formation in lactating women receiving SARS-CoV-2 vaccination, documenting the antibody isotypes, titers, duration, and transfer into milk over time.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
As the global and pandemic spread of the novel coronavirus (SARS-CoV-2, COVID-19) continues, many knowledge gaps remain regarding the epidemiology and transmission of infection, the immunological responses after viral exposure, and the immunological protection after vaccine administration.
Cincinnati had its first confirmed case of COVID-19 on March 14, 2020, and despite extensive shelter-in-place and social distancing efforts, community spread has continued over the past 10 months with several distinct infection surges.
As SARS-CoV-2 vaccines are becoming available in early 2021, it is important to understand the immunological effects of these vaccines and to contrast them to the effects of natural infection.
Of particular interest are the immunological effects of SARS-CoV-2 vaccines for lactating women, and whether breast milk will include secretory antibodies against the virus that potentially confer protection to the breastfeeding infant.
The investigators have a unique but time-limited opportunity to track the humoral immunological responses of SARS-CoV-2 vaccination among lactating women.
The investigators designed Antibody Detection of Vaccine-Induced Secretory Effects (ADVISE) to collect and analyze serial breast milk samples for secretory antibody responses, along with periodic blood testing of the mothers and their breastfeeding children.
In ADVISE, the investigators will document the prevalence and cumulative incidence of secretory antibody responses to SARS-CoV-2 vaccines, and gain insights into the protective immunological effects of elective vaccine administration.
Study Type
Observational
Enrollment (Actual)
61
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
Lactating mothers receiving the SARS-CoV-2 (COVID-19) vaccine.
Description
Inclusion Criteria:
- Age ≥ 18.0 years at the time of enrollment
- Currently lactating mothers
- Planning to receive the SARS-CoV-2 vaccine in the next 60 days, or vaccinated with the SARS-CoV-2 vaccine within the past 60 days
- Cell phone that can be used for text messaging or web-based viewing of surveys
- Willing and able to provide informed consent
- Ability to comply with all study related evaluations and follow-up
Exclusion Criteria:
- Any condition or illness that makes study participation ill-advised
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lactating Mothers
Lactating mothers who plan to receive or have received the SARS-CoV-2 vaccine within 60 days.
|
Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit.
Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IgA antibodies against Spike protein
Time Frame: 12 months
|
A 3-month cumulative prevalence of IgA antibodies against Spike protein after the completed administration of the SARS-CoV-2 vaccine.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 antibodies
Time Frame: 12 months
|
The associations between maternal serum antibodies (onset, titer, duration) and breast milk antibodies against SARS-CoV-2, as well as comparisons of antibody responses after vaccine to natural infection.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Russell Ware, Children's Hospital Medical Center, Cincinnati
- Principal Investigator: Julie Ware, Children's Hospital Medical Center, Cincinnati
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 19, 2021
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
May 17, 2021
First Submitted That Met QC Criteria
May 17, 2021
First Posted (Actual)
May 20, 2021
Study Record Updates
Last Update Posted (Actual)
August 29, 2023
Last Update Submitted That Met QC Criteria
August 28, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADVISE (Company Internal)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on SARS-CoV-2 vaccine
-
Stemirna TherapeuticsNot yet recruiting
-
Sanofi Pasteur, a Sanofi CompanyGlaxoSmithKlineActive, not recruitingCOVID-19Honduras, United States, Australia, France, Kenya, Mexico, New Zealand, Panama, Spain, United Kingdom
-
Shanghai Municipal Center for Disease Control and...China National Biotec Group Company LimitedNot yet recruitingMeasles | Rubella | Mumps | Varicella | SARS-CoV-2 InfectionChina
-
Sanofi Pasteur, a Sanofi CompanyTerminatedCOVID-19United States, Australia, Brazil, Honduras
-
GeoVax, Inc.National Cancer Institute (NCI); City of Hope Medical CenterActive, not recruitingCOVID-19 InfectionUnited States
-
Sinovac Research and Development Co., Ltd.Active, not recruiting
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Hospitales Universitarios Virgen del RocíoActive, not recruitingHIV Infection | SARS-CoV-2 RNA VaccinesSpain
-
University Hospital, CaenCompleted
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia | COVID-19 InfectionUnited States